Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - spironolakton - tablett - 100 mg - spironolakton 100 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - spironolakton - filmdragerad tablett - 25 mg - spironolakton 25 mg aktiv substans - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm healthcare a/s - spironolakton - tablett - 25 mg - spironolakton 25 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - spironolakton - tablett - 25 mg - laktosmonohydrat hjälpämne; spironolakton 25 mg aktiv substans - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - spironolakton - filmdragerad tablett - 50 mg - spironolakton 50 mg aktiv substans - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

pfizer ab - spironolakton - tablett - 50 mg - spironolakton 50 mg aktiv substans; laktosmonohydrat hjälpämne - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm healthcare a/s - spironolakton - tablett - 50 mg - laktosmonohydrat hjälpämne; spironolakton 50 mg aktiv substans; natriumlaurilsulfat hjälpämne - spironolakton

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz gmbh - hydroklortiazid; lisinoprildihydrat - tablett - 10 mg/12,5 mg - lisinoprildihydrat 10,89 mg aktiv substans; mannitol hjälpämne; hydroklortiazid 12,5 mg aktiv substans - lisinopril och diuretika

Europeiska unionen - svenska - EMA (European Medicines Agency)

krka, d.d., novo mesto - irbesartan, hydroklortiazid - hypertension - agenter som verkar på renin-angiotensinsystemet - behandling av essentiell hypertoni. denna fasta doskombination är indicerad hos vuxna patienter vars blodtryck inte kontrolleras på adekvat sätt på irbesartan eller hydroklortiazid.

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. förutom vid nyligen diagnostiserad kml kronisk fas, det finns inga kontrollerade studier som visar på en klinisk nytta eller ökad överlevnad för dessa sjukdomar. .